This is an outdated version published on 10/14/2020. Read the most recent version.

OVERVIEW OF THE BRAZILIAN OUTCOMES FROM FIRST MULTICENTRIC STUDY WITH USE FROM DATABASE CIBMTR. A PILOT STUDY.

Authors

  • Cinthya Corrêa da Silva Hospital Israelita Albert Einstein
  • Leonardo Javier Arcuri Hospital Israelita Albert Einstein
  • Anderson João Simione Hospital Amaral Carvalho
  • Heliz Regina Alves das Neves Hospital de Clínicas – Universidade Federal do Paraná
  • Bruna Letícia da Silva Santos Geraldo Bio Sana's Serviços Médicos
  • Afonso Celso Vigorito Universidade Estadual de Campinas
  • Vaneuza Araújo Moreira Funke Hospital de Clínicas – Universidade Federal do Paraná
  • Marcos Paulo Colella Universidade Estadual de Campinas
  • Andreza Alice Feitosa Ribeiro Hospital Israelita Albert Einstein
  • Vanderson Geraldo Rocha Hospital das Clinicas da Universidade de São Paulo
  • Iracema Esteves Hospital Israelita Albert Einstein
  • Carmem Bonfim Hospital de Clínicas – Universidade Federal do Paraná
  • Victor Gottardello Zecchin Grupo de Apoio ao Adolescente e à Criança com Câncer
  • Fernando Barroso Duarte Hospital Universitário Walter Cantídio
  • Roberto Luiz da Silva Bio Sana's Serviços Médicos
  • Cintia Monteiro Grupo de Apoio ao Adolescente e à Criança com Câncer
  • Germison Silva Lopes Hospital Universitário Walter Cantídio
  • Larissa Codogno Guzelotto Universidade Estadual de Campinas
  • Samir Nabhan Hospital de Clínicas – Universidade Federal do Paraná
  • Vergílio Antonio Rensi Colturato Hospital Amaral Carvalho
  • Nelson Hamerschlak Hospital Israelita Albert Einstein

DOI:

https://doi.org/10.46765/2675-374X.2020v2n1p55-62

Keywords:

Hematopoietic Cell Transplant, CIBMTR, Outcomes, Cox model, Kaplan Meier, Outcomes and Brazil.

Abstract

To better understand the outcomes of HSCT in Brazil, we conducted a multicenter study using the CIBMTR database. Seven participating centers extracted their own data through the Data Back to Center tool. Main indications for HSCT-auto were MM(51%), NHL(18%) and HL(17%); Allogeneic, AML(24%), ALL(23%) and SAA(15%). For acute leukemias, risk of death was higher in the 18-40 years group (HR=1.18,p=0.022), 40-60(HR=1.19,p<0.001) and 60+(HR=1.39,p=0.007), compared with 0-18 years, in ALL (HR=1.05,p <0.001, compared with AML) and with partially-matched related donor (HR=1.59,p= 0.003, compared with matched sibling), while URD was not. HSCT in CR2+(HR=1.28,p=0.01) and relapse (HR=2.44,p< 0.001) were risk factors for death. 49%(95CI:44-52)52%(95CI:43-62)45%(95CI:39-51) and 55%(95CI:49-63), somewhat poorer than the CIBMTR: 62 and 70%, respectively.  Limited access to novel drugs for most centers and lack of molecular risk information are possible explanations for these differences. Further studies are necessary to better evaluate our findings and the DBtC tool enables multicenter studies.

Downloads

Published

10/14/2020

Versions

How to Cite

da Silva, C. C., Arcuri, L. J., Simione, A. J., das Neves, H. R. A., Geraldo, B. L. da S. S., Vigorito, A. C., Funke, V. A. M., Colella, M. P., Ribeiro, A. A. F., Rocha, V. G., Esteves, I., Bonfim, C., Zecchin, V. G., Duarte, F. B., da Silva, R. L., Monteiro, C., Lopes, G. S., Guzelotto, L. C., Nabhan, S., Colturato, V. A. R., & Hamerschlak, N. (2020). OVERVIEW OF THE BRAZILIAN OUTCOMES FROM FIRST MULTICENTRIC STUDY WITH USE FROM DATABASE CIBMTR. A PILOT STUDY. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(3), 55–62. https://doi.org/10.46765/2675-374X.2020v2n1p55-62

Issue

Vol. 1 No. 3 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

Most read articles by the same author(s)

1 2 3 4 5 6 > >>